Fig. 4

MA2 protects against cisplatin-induced cytotoxicity in bladder cancer cells. a 5637 and T24 cells were incubated with different concentrations of cisplatin for 48 h, and cell viability was measured with the CCK-8 kit. b 5637 and T24 cells were incubated with different concentrations of MA2 for 48 h, the cell viability was measured with the CCK-8 kit. c 5637 and T24 cells were incubated with selected concentration of cisplatin in the presence or absence of MA2 for 48 h, and the cell viability was measured with the CCK-8 kit. (*P < 0.05)